Christine Emnett, PhD

Patent Agent
Norton Rose Fulbright US LLP
christine.emnett@nortonrosefulbright.com
Christine
Emnett
Christine Emnett, PhD
St. Louis
Suite 800
8001 Forsyth Blvd
St. Louis
Missouri
63105
United States
+1 314 505 8850

Christine Emnett, PhD, focuses her practice on patent preparation and prosecution in the life sciences and biotechnology sectors. Leveraging her technical background in biomedical sciences, Christine has handled matters involving neuroscience and small-molecule pharmacology, CRISPR-associated gene editing, gene therapy (including viral vector delivery systems), nucleic acid-based technologies, protein- and biologic-based therapeutics including antibodies and fusion proteins, cell-based therapies including CAR-T cells, biomarkers and associated detection assays and related technologies. She also performs patentability searches as well as freedom to operate (FTO) and landscape analysis. She has advised small to multinational clients in the biotechnology space.

Representative experience

  • Technical and representative experience with neuroscience and small‑molecule pharmacology, including patent drafting and prosecution in small‑molecule pharmacology, chemical structure representation and small‑molecule claim drafting and doctoral and postdoctoral training in electrophysiology, receptor signaling and drug interactions involving neurotransmitter receptors (including NMDA, AMPA and dopamine receptors) with a focus on small‑molecule agonists and antagonists.

  • Representative experience reflecting in-depth technical knowledge of gene therapy, gene editing and nucleic acid‑based technologies, including viral vector and lipid nanoparticle (LNP) delivery systems (including targeted organ delivery using cell‑specific lipids), CRISPR‑Cas gene‑editing platforms and antisense oligonucleotide therapeutics, supported by extensive patent drafting and prosecution experience across gene therapy, gene editing and nucleic acid‑based modalities.

  • Technical and representative experience with protein‑ and biologic‑based technologies, including large‑molecule constructs and fusion proteins (including CRISPR‑associated endonucleases), antibodies and antibody‑based platforms, therapeutic peptides, T‑cell receptor (TCR) and immune receptor systems and neoantigen‑based cancer vaccines, supported by extensive patent drafting and prosecution experience across therapeutic protein modalities, complemented by graduate‑level training in receptor protein signaling and ligand‑receptor interactions.

  • Representative experience with cell‑based therapeutic technologies, including induced pluripotent stem cell (iPSC) platforms—particularly gene‑edited allogeneic donor cells—fibroblast and chondrocyte‑based applications, and immune cell therapies such as CAR‑T, dendritic cell (DC) and NK cell systems.

  • Representative and technical experience with diagnostic and companion diagnostic technologies, including biomarker detection methods integrated with therapeutic selection and treatment steps, gene expression profiling associated with disease states, protein‑based diagnostic assays and detection methods (including mass spectrometry and specialized molecular reagents) and diagnostic approaches based on circulating cell populations, supported by undergraduate research training in gene allele detection methods (including PCR and ELISA‑based assays) and mass spectrometry techniques (including MALDI‑TOF).

  • Experience with sequencing and data analysis technologies, including handling sequence data and sequence listings, applications involving sequencing‑based analytical workflows, barcoding strategies and advanced analysis and manipulation of gene expression datasets.

  • Experience with computational biology approaches, including analysis of gene‑editing outcomes and datasets associated with genome editing technologies.

Education

  • PhD, Biological and Biomedical Sciences – Neurosciences, Washington University in St. Louis, 2014
  • BS, Biochemistry, summa cum laude, Mount Saint Mary’s University, 2009

Christine was registered in 2017 with United States Patent and Trademark Office (USPTO).

Admissions

  • US Patent and Trademark Agent

Publications

  • First author, “Interaction between positive allosteric modulators and trapping blockers of the NMDA receptor channel,” British Journal of Pharmacology, March 2015
  • First author, "Electrophysiology of Neurons," Neural Stem Cell Assays (2014): 179-187
  • First author, “Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine,” Molecular Pharmacology, December 2013
  • First author*, “Synaptic NMDA receptors mediate hypoxic excitotoxic death,” Journal of Neuroscience, May 2012 (*published under maiden name)
Bio